Hepatitis B virus (HBV) infection has been one of the most important public health problems, however, no complete cure is currently available. Although interferon (IFN)-α has been clinically used as a drug for chronic hepatitis B therapy because of its advantages including a higher rate of HBsAg/HBeAg seroconversion and a lower rate of recurrence after cessation of treatment, only 20%-40% of patients respond well to IFN therapy, thus hampering its clinical application. In recent years, based on the in vitro HBV replication and infection cell models, animal models and patient cohort with hepatitis B and by using a variety of methods, studies have been made. On the one hand, to identify new mechanisms underlying the IFN-and IFN-induced genes-mediated anti-HBV activities and signaling transduction, on the other hand, to reveal the effect and mechanisms of HBV replication and viral proteins in regulating the innate immune signaling pathways and IFN induction and antiviral action, based on which new strategies and approaches for optimization of IFN-based therapy and for a HBV cure have been further explored. This review mainly introduces the research findings of author's group and the future development is prospected.
|Original language||Chinese (Simplified)|
|Number of pages||6|
|Journal||Fudan University Journal of Medical Sciences|
|Publication status||Published - 25 Nov 2017|